The Emerging Innovative Pharmaceutical Enterprises in China
Building on the China Pharmaceutical Innovation and Invention Index, which assesses the overall innovation strength of leading Chinese pharmaceutical companies, here […]
strategy
Revitalizing Pharma Collaborations: The Reblozyl Case Study
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about
Joint Clinical Assessment (EU HTA) Explained
A Comprehensive Exploration of Competitive Intelligence, Knowledge-Sharing, and Strategic Optimization in the Evolving Landscape of EU Health Technology Assessments. The
Challenges in Hemoglobinopathies Projects and the Support of KOL Match
There are over 7,000 rare diseases described, affecting about 20-30 million people in the U.S. alone, according to the NIH. While each condition has its specificities, there are common challenges in the rare disease space, such as finding patients and leveraging centers of excellence and referral networks. This article discusses such challenges and how partnering with SAI’s subject matter experts can help overcome them.